Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Anti-Myelin Oligodendrocyte Glycoprotein (MOG), Serum

CPT: 86255

Special Instructions

If reflex test is performed, additional charges/CPT code(s) may apply.

Related Documents

Specimen Requirements




2 mL

Minimum Volume

1 mL (Note: This volume does not allow for repeat testing.)


Serum from a red-top tube

Storage Instructions

Room temperature

Stability Requirements



Room temperature

7 days


7 days


7 days

Freeze/thaw cycles

Stable x3

Causes for Rejection

Gross hemolysis; grossly lipemic; Serum Separator Tube (SST™)

Test Details


Diagnosis of inflammatory demyelinating diseases (IDD) with similar phenotype to neuromyelitis optica spectrum disorder (NMOSD), including optic neuritis (single or bilateral) and transverse myelitis; diagnosis of autoimmune myelin oligodendrocyte glycoprotein (MOG)-opathy; diagnosis of neuromyelitis optica (NMO); distinguishing NMOSD, acute disseminated encephalomyelitis (ADEM), optic neuritis, and transverse myelitis from multiple sclerosis early in the course of disease; diagnosis of ADEM; prediction of a relapsing disease course


MOG IgG antibody titers may assist in monitoring disease course and prognosis, but their role is imperfect. Antibody titers may increase but may not be predictive of relapses or attacks. MOG IgG antibodies may become undetectable with immunosuppression, but this does not necessarily indicate clinical response.

Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.


Immunofluorescence (IFA)


Apiwattanakul M, Popescu BF, Matiello M, et al. Intractable vomiting as the initial presentation of neuromylitis optica. Ann Neurol. 2010 Nov;68(5):757-761.21031587
Hyun JW, Woodhall MR, Kim SH, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurosurg Psychiatry. 2017 Oct;88(10):811-817.28684532
Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016 Sep 26;13(1):279.27788675
Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 Dec 11-17:364(9451):2106-2112.15589308
Peschl P, Bradl M, Höftberger R, Berger T, Reindl M. Myelin Oligodendrocyte Gilcoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases. Front Immunol. 2017 May 8;8:52928533781
Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA, Neuromyelitis optica brain lesions localized at sites of high aquaporine 4 expression. Arch Neurol. 2006 Jul;63(7):964-968.16831965
Reindl M, Jarius S, Rostasy K, Berger T. Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they? Curr Opin Neurol. 2017 Jun;30(3):295-301.28248700
Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012 Feb 28;78(9):665-671; discussion 669.22302543
Waters P, Woodhall M, O'Conner KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurlogic disease. Neurol Neutoimmunol Neuroinflamm. 2015 Mar 19;2(3);e89.25821844
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):117-189.26092914
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007 Sep;6(9):805-815.17706564

For Providers

Please login to order a test

Order a Test

© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at